Home » Stocks » CDXI

Cardax Inc. (CDXI)

Stock Price: $1.62 USD 0.00 (0.00%)
Updated Jan 15, 2021 9:30 AM EST - Market closed
Market Cap 1.22M
Revenue (ttm) 615,280
Net Income (ttm) -5.50M
Shares Out 755,847
EPS (ttm) -7.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.62
Previous Close $1.62
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.62
Day's Range 1.62 - 1.62
Day's Volume 0
52-Week Range 1.15 - 19

News

There are no news available yet.

About CDXI

Cardax, a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharma... [Read more...]

Industry
Biotechnology
CEO
David G. Watumull
Employees
11
Stock Exchange
OTCMKTS
Ticker Symbol
CDXI
Full Company Profile

Financial Performance

In 2019, Cardax's revenue was $710,949, a decrease of -52.94% compared to the previous year's $1.51 million. Losses were -$5.09 million, 26.6% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Cardax is 1.00, which is a decrease of -38.27% from the latest price.

Price Target
$1.00
(-38.27% downside)